Acute blood loss stimulates fibroblast growth factor 23 production

American Journal of Physiology - Renal Physiology

Volumn 314, Issue 1, 2018, Pages F132-F139

  Rabadi, Seham ^a   Udo, Ikemesit ^a   Leaf, David E ^b   Waikar, Sushrut S ^b   Christov, Marta ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anemia; Bleeding; Erythropoietin; FGF23; Iron

Indexed keywords

CALCIUM PHOSPHATE; CREATININE; ERYTHROPOIETIN; FERRITIN; FIBROBLAST GROWTH FACTOR 23; IRON; MESSENGER RNA; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; CALCIUM; FIBROBLAST GROWTH FACTOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD VOLUME; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CELL LINEAGE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; GENE EXPRESSION; HOSPITAL ADMISSION; HUMAN; HYPOXIA; INTENSIVE CARE UNIT; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURGICAL INTENSIVE CARE UNIT; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; BLOOD; C57BL MOUSE; DRUG EFFECT; ERYTHROPOIESIS; HOMEOSTASIS; METABOLISM; OPERATIVE BLOOD LOSS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD LOSS, SURGICAL; CALCIUM; ERYTHROPOIESIS; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; IRON; MICE, INBRED C57BL; MODELS, BIOLOGICAL;

EID: 85043490240     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00081.2017     Document Type: Article

References (31)

1. Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol 25: 564–572, 2014. doi:10.1681/ASN.2013040355.
2. Bergwitz C, Jüppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med 61: 91–104, 2010. doi:10.1146/annurev.med.051308.111339.
3. Carrillo-López N, Panizo S, Alonso-Montes C, Román-García P, Rodríguez I, Martínez-Salgado C, Dusso AS, Naves M, Cannata- Andía JB. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 90: 77–89, 2016. doi:10.1016/j.kint.2016.01.024.
4. Coe LM, Madathil SV, Casu C, Lanske B, Rivella S, Sitara D. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 289: 9795–9810, 2014. doi:10.1074/jbc.M113.527150.
5. David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89: 135–146, 2016. doi:10.1038/ki.2015.290.
6. Eckardt KU, Boutellier U, Kurtz A, Schopen M, Koller EA, Bauer C. Rate of erythropoietin formation in humans in response to acute hypobaric hypoxia. J Appl Physiol (1985) 66: 1785–1788, 1989.
7. Ehmke H, Just A, Eckardt KU, Persson PB, Bauer C, Kirchheim HR. Modulation of erythropoietin formation by changes in blood volume in conscious dogs. J Physiol 488: 181–191, 1995. doi:10.1113/jphysiol.1995.sp020956.
8. Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108: E1146–E1155, 2011. doi:10.1073/pnas.1110905108.
9. Faul C, Amaral AP, Oskouei B, Hu M-C, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-o M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest 121: 4393–4408, 2011. doi:10.1172/JCI46122.
10. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359: 584–592, 2008. doi:10.1056/NEJMoa0706130.
11. Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol 311: F1369–F1377, 2016. doi:10.1152/ajprenal.00281.2016.
12. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96: 3541–3549, 2011. doi:10.1210/jc.2011-1239.
13. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305: 2432–2439, 2011. doi:10.1001/jama.2011.826.
14. Kidney Disease Improving Global Outcomes (KDIGO); Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2: 1–138, 2012. doi:10.1038/kisup.2012.2.
15. Knab VM, Corbin B, Andrukhova O, Hum JM, Ni P, Rabadi S, Maeda A, White KE, Erben RG, Jüppner H, Christov M. Acute parathyroid hormone injection increases C-terminal, but not intact fibroblast growth factor 23 levels. Endocrinology 158: 1130–1139, 2017. doi:10.1210/en.2016-1451.
16. Kuhrt D, Wojchowski DM. Emerging EPO and EPO receptor regulators and signal transducers. Blood 125: 3536–3541, 2015. doi:10.1182/blood-2014-11-575357.
17. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882–F889, 2010. doi:10.1152/ajprenal. 00360.2010.
18. Leaf DE, Christov M, Jüppner H, Siew E, Ikizler TA, Bian A, Chen G, Sabbisetti VS, Bonventre JV, Cai X, Wolf M, Waikar SS. Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int 89: 939–948, 2016. doi:10.1016/j.kint.2015.12.035.
19. Leaf DE, Jacob KA, Srivastava A, Chen ME, Christov M, Jüppner H, Sabbisetti VS, Martin A, Wolf M, Waikar SS. Fibroblast growth factor 23 levels associate with AKI and death in critical illness. J Am Soc Nephrol 28: 1877–1885, 2017. doi:10.1681/ASN.2016080836.
20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009. doi:10.7326/0003-4819-150-9-200905050-00006.
21. Miller ME, Rörth M, Stohlman F, Jr, Valeri CR, Lowrie G, Howard D, McGilvray N. The effects of acute bleeding on acid-base balance erythropoietin (Ep) production and in vivo P50 in the rat. Br J Haematol 33: 379–385, 1976. doi:10.1111/j.1365-2141.1976.tb03554.x.
22. Rossaint J, Oehmichen J, Van Aken H, Reuter S, Pavenstädt HJ, Meersch M, Unruh M, Zarbock A. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126: 962–974, 2016. doi:10.1172/JCI83470.
23. Scanni R, vonRotz M, Jehle S, Hulter HN, Krapf R. The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol 25: 2730–2739, 2014. doi:10.1681/ASN.2013101076.
24. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429–435, 2004. doi:10.1359/JBMR.0301264.
25. Siew ED, Matheny ME. Choice of Reference Serum Creatinine in Defining Acute Kidney Injury. Nephron 131: 107–112, 2015. doi:10.1159/000439144.
26. Singh S, Grabner A, Yanucil C, Schramm K, Czaya B, Krick S, Czaja MJ, Bartz R, Abraham R, Di Marco GS, Brand M, Wolf M, Faul C. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90: 985–996, 2016. doi:10.1016/j.kint.2016.05.019.
27. Tsai MH, Leu JG, Fang YW, Liou HH. High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) 95: e3049, 2016. doi:10.1097/MD.0000000000003049.
28. van Breda F, Emans ME, van der Putten K, Braam B, van Ittersum FJ, Kraaijenhagen RJ, de Borst MH, Vervloet M, Gaillard CA. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure. PLoS One 10: e0128994, 2015. doi:10.1371/journal.pone.0128994.
29. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28: 1793–1803, 2013. doi:10.1002/jbmr.1923.
30. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23: 411–419, 2014. doi:10.1097/01.mnh.0000447020.74593.6f.
31. Xiao Z, Huang J, Cao L, Liang Y, Han X, Quarles LD. Osteocytespecific deletion of Fgfr1 suppresses FGF23. PLoS One 9: e104154, 2014. doi:10.1371/journal.pone.0104154.